LevelJump Announces 2025 Financial Results

Sentiment Analysis
LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") , is pleased to announce its financial results for the year ended December 31, 2025. Financial and Operational Highlights Revenues were $19.1 million in 2025 compared to $17.7 million in revenues for 2024, a year over year revenue increase of 7.9%. Canadian Teleradiology Services, Inc., the Company's 100% owned subsidiary had EBITDA for 2025 of $3.84 million. 2025 Financial Results for fourth quarter and year Revenues of $5.1 million in Q4 2025 and $19.1 million for the year 2025 with a net loss from operations of $ for Q4 2025 and a net loss from operations of $815,018 for the year 2025. EBITDA of $(105,000) for Q4 2025 and $1,662,510 for the year 2025. Management Comments "2025 was a strong year, with revenues reaching $19.1 million - the highest in the Company's history," said Mitch Geisler, CEO. "We generated strong EBITDA from operations, driven by continued organic growth as demand for our services expands. The dip in Q4 EBITDA was largely attributable to legal and ancillary costs associated with the shareholder requisition, which are not expected to recur." Non-IFRS Financial Measures This news release contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as management uses them to evaluate the operating performance of the Company. The Company's determination of these non-IFRS measures may differ from other reporting issuers and therefore are unlikely to be comparable to similar measures presented by other companies. Further, these non-IFRS measures should not be considered in isolation or as a substitute for measures of performance or cash flows prepared in accordance with IFRS. These financial measures are included because management uses this information to analy...
Source: Newsfile Corp
This content is not intended as investment advice or a recommendation. Any opinions expressed are solely the personal views of each article.